CXCL10 and systemic sclerosis: To assess the activity of BLUE compounds in the context of autoimmune disease associated with aberrant Type I IFN activation, we also measured ISG expression and CXCL10 secretion levels of PBMCs from patients affected by Scleroderma (SSc)26 (Extended Data Table 3).